TACE联合艾迪注射液对乙肝合并肝癌患者HBVDNA和AFP的影响  

Impact of TACE combined with Aidi injection on HBV DNA and AFP of hepatitis B patients complicated with liver cancer

作　　者：张小灵[1] 陈立宇 

机构地区：[1]四川省武胜县人民医院感染科,四川武胜638400 [2]四川大学华西医院感染科

出　　处：《西南国防医药》2015年第6期600-602,共3页Medical Journal of National Defending Forces in Southwest China

摘　　要：比较肝动脉化疗栓塞（TACE）联合艾迪注射液与恩替卡韦降低乙肝合并肝癌患者甲胎蛋白（AFP）水平及对HBV DNA转阴率的影响。以2010年6月~2011年11月在我科室治疗的70例乙肝合并肝癌患者作为研究对象，随机分为恩替卡韦组和艾迪组，两组均联合TACE治疗。观察比较两组治疗后不同时间HBV DNA和AFP改变。恩替卡韦组总有效率（77.14%）与艾迪组（85.71%）比较无统计学差异（P〉0.05）；艾迪组TACE术后4~48 w的AFP均显著低于恩替卡韦组（P〈0.05）；除术后第1年两组HBV DNA转阴率无显著差异（P〈0.05）外，第2、3年恩替卡韦组HBV DNA转阴率分别为57.14%、71.43%，均显著低于艾迪组的80.00%和91.43%（P〈0.05）。艾迪注射液与恩替卡韦治疗乙肝合并肝癌均有显著疗效，比较而言，艾迪注射液可显著降低AFP水平，提高HBV DNA转阴率，故应将TACE联合艾迪注射液作为首选方案。To compare the effects of transarterial chemoembolization （TACE） combined with Aidi （AD） injection or entecavir on reduction of AFP levels of hepatitis B （HVB） patients complicated with liver cancer and study the impacts on negative conversion ratio of HBV DNA. Total 70 HVB patients complicated with liver cancers to receive treatment in our department from June 2010 to November 2011 were taken as the study subjects and randomly divided into entecavir group and AD group. The two groups received TACE combination therapy. The changes of HBV DNA and AFP in the two groups in different postoperative times were observed. The overall efficacy in entecavir group （77.14%） and AD group （85.71%） had no statistic difference （P〉0.05）. In 4-48 weeks after the operation, AFP in AD group was obviously lower than that in entecavir group （ P〈0.05）. In the 1st year after the operation, the negative conversion ratios of HBV DNA in the two groups had no obvious difference （ P〉0.05）, but in the 2nd and 3rd year, the negative conversion ratio of HBV DNA in entecavir group was 57.14%and 71.43%, respectively, lower than that in AD group （ 80.00%and 91.43%）（ P〈0.05）. Both AD injection and entecavir can achieve a significant curative effect in treatment of HVB complicated with liver cancer. Comparatively, AD injection can significantly reduce AFP level and increase the negative conversion ratio of HBV DNA. So TACE combined with AD injection should be taken as the preferred option.

关 键 词：肝动脉化疗栓塞 恩替卡韦 艾迪注射液 乙肝 肝癌 

分 类 号：R512.62[医药卫生—内科学]